Published in Blood on September 09, 2014
Navigating the bone marrow niche: translational insights and cancer-driven dysfunction. Nat Rev Rheumatol (2015) 0.90
3D tissue-engineered bone marrow as a novel model to study pathophysiology and drug resistance in multiple myeloma. Biomaterials (2015) 0.86
Dynamic interplay between bone and multiple myeloma: emerging roles of the osteoblast. Bone (2015) 0.83
Tissue-engineered 3D cancer-in-bone modeling: silk and PUR protocols. Bonekey Rep (2016) 0.81
Signaling Interplay between Bone Marrow Adipose Tissue and Multiple Myeloma cells. Front Endocrinol (Lausanne) (2016) 0.79
MicroRNAs: Novel Crossroads between Myeloma Cells and the Bone Marrow Microenvironment. Biomed Res Int (2016) 0.79
Ex Vivo Maintenance of Primary Human Multiple Myeloma Cells through the Optimization of the Osteoblastic Niche. PLoS One (2015) 0.78
Human vascular progenitor cells derived from renal arteries are endothelial-like and assist in the repair of injured renal capillary networks. Kidney Int (2016) 0.77
The Skeletal Cell-Derived Molecule Sclerostin Drives Bone Marrow Adipogenesis. J Cell Physiol (2017) 0.75
Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci (2016) 0.75
A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. Oncotarget (2016) 0.75
Adipose, Bone, and Myeloma: Contributions from the Microenvironment. Calcif Tissue Int (2016) 0.75
Primary myeloma interaction and growth in coculture with healthy donor hematopoietic bone marrow. BMC Cancer (2015) 0.75
High throughput chemical library screening identifies a novel p110-δ inhibitor that potentiates the anti-myeloma effect of bortezomib. Oncotarget (2016) 0.75
Three dimensional de novo micro bone marrow and its versatile application in drug screening and regenerative medicine. Exp Biol Med (Maywood) (2015) 0.75
Surface-tension driven open microfluidic platform for hanging droplet culture. Lab Chip (2016) 0.75
Innovative approaches to establish and characterize primary cultures: an ex vivo 3D system and the zebrafish model. Biol Open (2016) 0.75
Engineering 3D Models of Tumors and Bone to Understand Tumor-Induced Bone Disease and Improve Treatments. Curr Osteoporos Rep (2017) 0.75
Soluble Factors on Stage to Direct Mesenchymal Stem Cells Fate. Front Bioeng Biotechnol (2017) 0.75
Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A (2005) 167.46
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell (2005) 96.87
Statistical significance for genomewide studies. Proc Natl Acad Sci U S A (2003) 88.64
Mechanisms of bone metastasis. N Engl J Med (2004) 10.40
Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood (1999) 4.13
Osteoprotection by semaphorin 3A. Nature (2012) 3.40
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37
Deconstructing the third dimension: how 3D culture microenvironments alter cellular cues. J Cell Sci (2012) 2.89
Clinical role of microRNAs in cytogenetically normal acute myeloid leukemia: miR-155 upregulation independently identifies high-risk patients. J Clin Oncol (2013) 2.86
BM mesenchymal stromal cell-derived exosomes facilitate multiple myeloma progression. J Clin Invest (2013) 2.34
A unique three-dimensional model for evaluating the impact of therapy on multiple myeloma. Blood (2008) 2.25
A 3'-untranslated region (3'UTR) induces organ adhesion by regulating miR-199a* functions. PLoS One (2009) 2.24
Inhibitory effects of osteoblasts and increased bone formation on myeloma in novel culture systems and a myelomatous mouse model. Haematologica (2006) 2.11
MicroRNA-138 regulates osteogenic differentiation of human stromal (mesenchymal) stem cells in vivo. Proc Natl Acad Sci U S A (2011) 2.05
Suppression of bone formation by osteoclastic expression of semaphorin 4D. Nat Med (2011) 2.00
Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. Leukemia (2007) 1.86
Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood (2001) 1.83
P-selectin glycoprotein ligand regulates the interaction of multiple myeloma cells with the bone marrow microenvironment. Blood (2011) 1.77
miR-199a, a bone morphogenic protein 2-responsive MicroRNA, regulates chondrogenesis via direct targeting to Smad1. J Biol Chem (2009) 1.68
Effects of bisphosphonates on proliferation and osteoblast differentiation of human bone marrow stromal cells. Biomaterials (2005) 1.61
Human multipotent stromal cells from bone marrow and microRNA: regulation of differentiation and leukemia inhibitory factor expression. Proc Natl Acad Sci U S A (2008) 1.54
Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors. Leukemia (2000) 1.35
High-strength silk protein scaffolds for bone repair. Proc Natl Acad Sci U S A (2012) 1.22
Bone marrow stromal cell interaction reduces syndecan-1 expression and induces kinomic changes in myeloma cells. Exp Cell Res (2010) 1.21
Epidermal growth factor (EGF) treatment on multipotential stromal cells (MSCs). Possible enhancement of therapeutic potential of MSC. J Biomed Biotechnol (2010) 1.16
Hypoxia-mediated expression of 5-lipoxygenase-activating protein involves HIF-1alpha and NF-kappaB and microRNAs 135a and 199a-5p. J Immunol (2010) 1.14
Tgf-Beta inhibition restores terminal osteoblast differentiation to suppress myeloma growth. PLoS One (2010) 1.11
The ephrinB2/EphB4 axis is dysregulated in osteoprogenitors from myeloma patients and its activation affects myeloma bone disease and tumor growth. Blood (2009) 1.08
Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin Cancer Res (2011) 1.06
Bone marrow stromal cells from multiple myeloma patients uniquely induce bortezomib resistant NF-kappaB activity in myeloma cells. Mol Cancer (2010) 1.02
Mesenchymal stem cells exploit extracellular matrix as mechanotransducer. Sci Rep (2013) 1.00
Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway. Leukemia (2012) 0.98
Flexible and versatile as a chameleon-sophisticated functions of microRNA-199a. Int J Mol Sci (2012) 0.93
Effect of low-magnitude, high-frequency vibration on osteogenic differentiation of rat mesenchymal stromal cells. J Orthop Res (2011) 0.93
Upregulation of miR-135b is involved in the impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients. PLoS One (2013) 0.92
Impact of bortezomib on bone health in myeloma: a review of current evidence. Cancer Treat Rev (2012) 0.91
Ex-vivo dynamic 3-D culture of human tissues in the RCCS™ bioreactor allows the study of Multiple Myeloma biology and response to therapy. PLoS One (2013) 0.89
Stem Cell Implants for Cancer Therapy: TRAIL-Expressing Mesenchymal Stem Cells Target Cancer Cells In Situ. J Breast Cancer (2012) 0.88
Microenvironment: Neighbourhood watch. Nature (2011) 0.81
Bone anabolic agents for the treatment of multiple myeloma. Cancer Microenviron (2011) 0.81
Downregulation of ErbB3 by Wnt3a contributes to wnt-induced osteoblast differentiation in mesenchymal cells. J Cell Biochem (2012) 0.80
Semaphorin 3A induces mesenchymal-stem-like properties in human periodontal ligament cells. Stem Cells Dev (2014) 0.80
A comparison of cytokine production in 2-dimensional and 3-dimensional cultures of bone marrow stromal cells of multiple myeloma patients in response to RPMI8226 myeloma cells. Folia Histochem Cytobiol (2009) 0.79
The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future. Oncologist (2011) 0.78
The possible role of fibronectin in multiple myeloma. Int J Clin Lab Res (1994) 0.77